NCT02037074View on ClinicalTrials.gov

Study to Assess the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of EVP-6308 and the Potential of EVP-6308 to Affect the PK Properties of the Antipsychotic Regimen in Subjects With Schizophrenia Currently Receiving Stable Treatment With up to 2 Atypical Antipsychotics

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

December 31, 2014

Conditions
Schizophrenia
Interventions
DRUG

Drug: EVP-6308

Arms 1, 2, 3

DRUG

Placebo

Arm 4

Trial Locations (1)

Unknown

Long Beach

Sponsors
All Listed Sponsors
lead

FORUM Pharmaceuticals Inc

INDUSTRY

NCT02037074 - Study to Assess the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of EVP-6308 and the Potential of EVP-6308 to Affect the PK Properties of the Antipsychotic Regimen in Subjects With Schizophrenia Currently Receiving Stable Treatment With up to 2 Atypical Antipsychotics | Biotech Hunter | Biotech Hunter